Ipsen (STU:I7G) FFO


STU:I7G Ipsen SA STU:I7G
91 GF Score
Price €165.60
GF Value €132.58
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ipsen FFO?

FFO (Funds from operations) only applies to REITs.

STU:I7G
91GF Score
Ipsen SA STU:I7G
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipsen (STU:I7G) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €165.60 is trading 24.9% above its estimated GF Value™ of €132.58. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for STU:I7G:

  • FFO:
  • GF Value™: €132.58 vs. price of €165.60 (24.9% above fair value)
  • GF Score™: 91/100 with 7 warning signs

No single metric tells the full story. See the STU:I7G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
91GF Score

Get the complete analysis for STU:I7G

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€165.60
Price
€132.58
GF Value